Innovative Biobattery Offers New Hope for Drug-Free Cancer Treatment by Tumor Shrinkage

A groundbreaking biobattery developed through a collaboration between the University of Wollongong in Australia and Jilin University in China has demonstrated significant potential to combat tumors without relying on traditional drugs. Published in Science Advances, this innovative device utilizes biological processes to generate electrical energy directly within the body, targeting cancerous growths with remarkable efficiency. When placed around subcutaneous tumors, the biobattery caused a tumor size reduction of over 99.6%, shrinking from more than 1,000 mm³ to just 4 mm³ within 14 days.

The biobattery operates with two key electrodes—an anode and a cathode—using chemical reactions involving zinc and manganese ions, which create a localized environment that inhibits tumor growth. The device continuously releases these metal ions at the tumor site, helping the immune system identify and eliminate cancer cells while simultaneously delivering electrical stimulation that boosts immunotherapy responses.

Professor Gordon Wallace emphasized that this research expands upon previous work with biobatteries and highlights their potential in medical applications. He noted, "The idea was inspired by traditional implantable batteries but designed to interact directly with tissue, creating a chemical environment hostile to cancer development."

Professor Caiyun Wang explained that the released zinc and manganese ions activate the body's immune defenses, enhancing its ability to recognize and destroy tumor cells effectively in the targeted area. The approach could reduce the need for harsh pharmaceuticals, potentially lowering side effects and improving patient quality of life.

Jilin University’s Associate Professor Jia Xiaoteng added that this technology represents a novel electrochemical method for drug-free immunotherapy that could offer sustained and precise delivery of immune-activating substances. The next phase involves clinical and preclinical testing to translate these findings into practical treatment options.

Professor Wallace concluded by emphasizing the importance of international collaboration in addressing complex health challenges and stated, "We are committed to advancing this technology into real-world applications to help patients worldwide." This innovative work opens new pathways for cancer treatment, harnessing bioelectrochemical processes to shrink tumors effectively without relying on conventional drugs.